Urinary Bladder, Neurogenic Clinical Trial
Official title:
Clinical Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
Verified date | July 2018 |
Source | Spinal Singularity |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and extended period (up to 29 days) of home use.
Status | Completed |
Enrollment | 5 |
Est. completion date | June 30, 2018 |
Est. primary completion date | June 30, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Males age = 18 with clinical diagnosis of neurogenic lower urinary tract dysfunction (NLUTD) - Must be clinically suitable and capable of safely managing bladder using an intermittent voiding strategy Must have stable urinary management history with clean intermittent catheterization: no significant changes in bladder management regimen within past 12 months OR: Must have urodynamic profile suitable for CIC, as assessed via urodynamics study within past 12 months (including bladder capacity > 200mL without uninhibited bladder contractions) - Subject's lower urinary tract anatomy (lengths of proximal and distal urethral must fall within the ranges serviceable by the Connected Catheter device, as specified in the investigational device instructions for use. - For cases of NLUTD due to spinal cord injury, the subject must be in medically stable condition (i.e. post-spinal shock phase) Exclusion Criteria: - Active symptomatic urinary tract infection, as defined in this protocol (subjects may receive the CoCath Device after UTI has been treated) - Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days) - Significant risk profile or recent history of clinically significant autonomic dysreflexia (e.g. History of hospitalization due to AD within past 12 months) - Significant intermittent urinary incontinence (between catheterizations) - Uninhibited bladder contractions and/or vesico-ureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. botox injections) - Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy, urine analysis, and blood labs) - Urinary tract inflammation or neoplasm - Urinary fistula - Bladder diverticulum (outpouching) > 5cm in size - Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months) - Impaired kidney function or renal failure (assessed via blood creatinine levels > 2 mg/dL) - Active gross hematuria - Active urethritis - Bladder stones - Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device - Individuals allergic or otherwise unable to take oral antibiotics - Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the CoCath System |
Country | Name | City | State |
---|---|---|---|
United States | West Coast Urology, 11411 Brookshire Avenue, Suite 508 | Downey | California |
United States | Tri Valley Urology, 25495 Medical Center Dr., Suite 204 | Murrieta | California |
Lead Sponsor | Collaborator |
---|---|
Spinal Singularity |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from genito-urinary injury/trauma | Improved bladder management without injury or trauma to genito-urinary tract | 29 Days | |
Primary | Successful Acute Performance- I | To evaluate successful retention of Connected Catheter and Void | On the day of Connected Catheter Insertion | |
Primary | Successful Acute Performance -II | To evaluate successful bladder voiding with Connected Catheter | On the day of Connected Catheter Insertion | |
Primary | Successful Acute Performance- III | To evaluate successful removal of Connected Catheter | On the day of Connected Catheter Insertion | |
Primary | Successful Acute Performance- IV | To evaluate successful post-void sealing of Connected Catheter Valve | On the day of Connected Catheter Insertion | |
Primary | Successful Home-Use Performance | Successful Home-Use using same measures as Acute Performance | 29 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05141487 -
Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
|
||
Completed |
NCT01920243 -
Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI)
|
N/A | |
Completed |
NCT04528784 -
Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis
|
N/A | |
Enrolling by invitation |
NCT03336424 -
Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.
|
N/A | |
Not yet recruiting |
NCT05075642 -
Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
|
||
Completed |
NCT02600715 -
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
|
Phase 4 | |
Recruiting |
NCT04128709 -
Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use
|
N/A | |
Enrolling by invitation |
NCT05740527 -
Ambulatory Closed-loop Stimulation for Bladder Control
|
N/A | |
Completed |
NCT02501928 -
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
|
Phase 3 | |
Recruiting |
NCT06336304 -
NXT Post-Market Clinical Follow-up
|
||
Completed |
NCT06445426 -
Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction
|
||
Recruiting |
NCT04819360 -
Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
|
Phase 4 | |
Terminated |
NCT02044510 -
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01557244 -
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
|
Phase 3 | |
Recruiting |
NCT05380661 -
Heart Rate Variability and Anxiety During Urinary Bladder Catheterization
|
N/A | |
Recruiting |
NCT04193709 -
Recovery of Bladder and Sexual Function After Human Spinal Cord Injury
|
N/A | |
Completed |
NCT02582151 -
Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
|
N/A | |
Active, not recruiting |
NCT05232253 -
Cystoealstometer (Bladder Monitor Device)-Home Use
|
N/A | |
Completed |
NCT02673047 -
Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder
|
N/A | |
Completed |
NCT01773213 -
Detrusor Contraction During the Ice-water-test
|
N/A |